search
Back to results

RSPR-007 Mannitol Challenge Trial

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
Denmark
Study Type
Interventional
Intervention
CRD007
Placebo
Sponsored by
RSPR Pharma AB
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent
  • Age ≥18 and <50 years
  • Diagnosis of asthma

Exclusion Criteria:

  • Clinical significant comorbidities
  • Lower respiratory tract infection <6 weeks prior to Visit 1
  • Others, as specified in the protocol

Sites / Locations

  • Hvidovre Hospital
  • Bisbebjerg Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Active Comparator

Active Comparator

Arm Label

Placebo

CRD007 Low dose

CRD007 High dose

Arm Description

Matching placebo tables are given as a single dose

"Low dose" of CRD007 (pemirolast sodium) given as a single dose

"High dose" CRD007 (pemirolast sodium) given as a single dose

Outcomes

Primary Outcome Measures

PD15 for mannitol after treatment with CRD007 and placebo
The FEV1 value taken after the 0 mg capsule is taken as pre-challenge FEV1 and used to calculate the percentage decrease in FEV1 in response to the mannitol challenge. The test ends when the FEV1 has fallen by 15% or more (PD15)

Secondary Outcome Measures

Full Information

First Posted
November 17, 2015
Last Updated
November 15, 2016
Sponsor
RSPR Pharma AB
search

1. Study Identification

Unique Protocol Identification Number
NCT02609334
Brief Title
RSPR-007 Mannitol Challenge Trial
Official Title
A Double-Blind, Randomised, Placebo-controlled, Cross-over, Phase 2 Mannitol Challenge Trial, Investigating the Efficacy of CRD007 in Adult Subjects With Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
March 2015 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
July 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RSPR Pharma AB

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a double-blind, randomised, placebo-controlled, cross-over, Phase 2 trial evaluating two doses (a low and a high) of CRD007 for the treatment of asthmatic trial subjects with a positive asthma test (mannitol challenge) prior to enrolment.
Detailed Description
The present trial will include subjects with diagnosed asthma in a provocation model which mimics assessments of asthma control. Mannitol challenge is an indirect asthma provocation test, which requires the presence of inflammatory cells, particularly mast cells, in the airways. The trial involved in total 5 subject visits and will last for a maximum of 30 days for each subject from Visit 2 (Randomisation) to Visit 5 (Follow up). Visit 2,3, and 4 will be treatment visits where Investigational Medicinal Product (IMP) is administrated 3 hours before the Mannitol challenge.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matching placebo tables are given as a single dose
Arm Title
CRD007 Low dose
Arm Type
Active Comparator
Arm Description
"Low dose" of CRD007 (pemirolast sodium) given as a single dose
Arm Title
CRD007 High dose
Arm Type
Active Comparator
Arm Description
"High dose" CRD007 (pemirolast sodium) given as a single dose
Intervention Type
Drug
Intervention Name(s)
CRD007
Other Intervention Name(s)
Pemirolast sodium
Intervention Description
One single dose given 3 hours prior to Mannitol challenge
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
One single dose given 3 hours prior to Mannitol challenge
Primary Outcome Measure Information:
Title
PD15 for mannitol after treatment with CRD007 and placebo
Description
The FEV1 value taken after the 0 mg capsule is taken as pre-challenge FEV1 and used to calculate the percentage decrease in FEV1 in response to the mannitol challenge. The test ends when the FEV1 has fallen by 15% or more (PD15)
Time Frame
Forced expiratory volume at one second (FEV1) manoeuvres are performed 60 seconds after each dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent Age ≥18 and <50 years Diagnosis of asthma Exclusion Criteria: Clinical significant comorbidities Lower respiratory tract infection <6 weeks prior to Visit 1 Others, as specified in the protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vibeke Backer, MD
Organizational Affiliation
Bispebjerg Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hvidovre Hospital
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark
Facility Name
Bisbebjerg Hospital
City
København NV
ZIP/Postal Code
2400
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

RSPR-007 Mannitol Challenge Trial

We'll reach out to this number within 24 hrs